UK markets open in 7 hours 43 minutes
  • NIKKEI 225

    28,029.57
    0.00 (0.00%)
     
  • HANG SENG

    23,766.69
    -22.21 (-0.09%)
     
  • CRUDE OIL

    67.82
    +1.56 (+2.35%)
     
  • GOLD FUTURES

    1,784.80
    +0.90 (+0.05%)
     
  • DOW

    34,580.08
    -59.72 (-0.17%)
     
  • BTC-GBP

    37,015.57
    -515.99 (-1.37%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • ^IXIC

    15,085.47
    -295.83 (-1.92%)
     
  • ^FTAS

    4,059.32
    -4.57 (-0.11%)
     

ProQR Announces Upcoming Investor Conferences in November and December

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following upcoming investor conferences:

  • Stifel 2021 Virtual Healthcare Conference
    Monday, November 15, 11:20-11:50am EST – Fireside chat

  • Evercore ISI 4th Annual HealthCONx Conference
    Thursday, December 2, 9:40-10:00am EST – Fireside chat

Presentation and webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in these conferences. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting